Health IT, BioPharma

Vineti, Deloitte Consulting partner software systems to improve cell, gene therapy access

The partnership will combine Vineti's cloud-based system for cell therapy logistics with Deloitte Consulting's ConvergeHEALTH Patient Connect.

A company that uses cloud technology to enable tracing and traceability for cell and gene therapies is partnering with a consulting firm that has developed a suite of software products designed to enable life sciences clients to respond to the shift to value-based and personalized medicine.

Vineti and Deloitte Consulting announced the partnership Tuesday, saying that the combination of their products – Vineti’s “platform of record” and Deloitte’s ConvergeHEALTH Patient Connect – will enable life sciences innovators to have more efficient access to cell therapies.

“This relationship will lead to holistic, end-to-end services that connect automated supply chain workflows with a new level of support to the broader ecosystem and to patients,” Vineti CEO Amy DuRoss said in a statement. “Together, Vineti and ConvergeHEALTH Patient Connect’s care pathway support will bring an increasingly interdependent stakeholder group together in support of the patient in real time. This can create an opportunity not just for better service and support, but also for better overall patient access, safety and outcomes.”

Vineti – founded by the Mayo Clinic and General Electric – works with more than 65 medical centers and is expanding internationally. ConvergeHEALTH Patient Connect supports more than 300,000 patients in 17 countries.

In a subsequent phone interview, DuRoss said that the two companies’ product offerings were complementary and would allow integration of Deloitte’s patient reach with Vineti’s support for the cell therapy supply chain. “We see the two coming together to provide a full platform of support,” she said. DuRoss took part in a panel about CAR-T and gene therapy at the MedCity CONVERGE conference in Philadelphia in July.

Indeed, while cell therapies like CAR-T have a lot of promise, there are also some issues that have to be hashed out. One question that remains is whether manufactures can handle the volume that will come as therapies move into increased commercial development, an especially important issue when dealing with fast-acting cancers like pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) is approved for pediatric ALL and DLBCL, while Gilead Sciences’ Yescarta (axicabtagene ciloleucel) is approved for DLBCL.

Photo: mediaphotos, Getty Images

Shares0
Shares0